Follicle stimulating hormone promotes production of renin through its receptor in juxtaglomerular cells of kidney

Zhen Yu1,2†, Jing Yang3†, Wen-Jie Huang1, Tao Zhang1, Xiao-Min Li1, Wei Zhao1, Xiao-Yong Li1 and Yong-Chao Lu1*

Abstract

Background: Post-menopausal hypertension has been attributed solely to declining estrogen levels. The purpose of the research is to elucidate the mechanism by which follicle stimulating hormone (FSH) increases renin production involved in the regulation of blood pressure.

Methods: The expression of follicle stimulating hormone receptors (FSHRs) in renal juxtaglomerular cells and a As4.1 juxtaglomerular mouse cell line was evaluated. We established a mouse model by ovariectomy (OVX). Ovariectomized mice were treated with gonadotropin-releasing hormone agonist (GnRHa) (OVX + GnRHa). Ovariectomized mice initially received physiological doses of estrogen and were then injected with recombinant FSH (OVX + E + FSH).

Results: We found that FSHR was expressed in mouse renal juxtaglomerular cells labeled by renin antibody and in As4.1 cells. FSH promoted renin synthesis via Gsα-coupled FSHRs that activated protein kinase A, cyclic adenosine monophosphate (cAMP) response element-binding protein, extracellular signal-regulated kinase (Erk1/2), Protein kinase B (AKT), and c-Jun N-terminal kinase signaling pathways in As4.1 cells. We found increased serum FSH levels in the ovariectomized mouse with concurrent increases in renin, angiotensin II, heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial blood pressure (MAP). Additionally, increases in serum renin, angiotensin II, HR, SBP, DBP, and MAP were reduced by the additional injection of GnRHa. Exogenous FSH administration completely reversed decreases in renin, angiotensin II, HR, SBP, DBP, and MAP even in mice that received physiological doses of estrogen to maintain normal estradiol levels.

Conclusions: Elevated FSH stimulates renin production involving a mechanism that may be relevant to the expression of FSH receptors in renal juxtaglomerular cells.

Keywords: FSHR, Juxtaglomerular cell, Renin

Introduction

Hypertension is one of the leading risk factors for cardiovascular disease [1, 2]. Aging in both men and women is characterized by increases in blood pressure (BP) [1–4]. However, age-related increases are more rapid in women than in men [4–7], and the prevalence of hypertension in postmenopausal women is higher than that in men. In the United States, > 75% of women over 60 years old are hypertensive [5, 6]. A study showed that the percentage

*Correspondence: 5312055@zju.edu.cn
†Zhen Yu and Jing Yang are the first authors and contributed equally to this work
1 Department of Reproductive Endocrinology, Women's Hospital, Zhejiang University School of Medicine, No. 1 Xueshi Road, Hangzhou 310006, Zhejiang, China
Full list of author information is available at the end of the article
of individuals with uncontrolled BP was 50.8 ± 2.1% in men and 55.9 ± 1.5% in women, although women were more likely to have their BPs measured within the previous 6 months [7]. Despite this, the study also showed that women were more likely to have poorly controlled hypertension, although drugs used to treat hypertension were similar in both sexes [7]. Thus, though antihypertensive methods are similar between men and women, and women are more likely to have their BPs measured, hypertension may be less well controlled in women. This suggests that perhaps the mechanisms responsible for hypertension in women may differ from those in men.

Follicle-stimulating hormone (FSH), a glycoprotein hormone derived from the pituitary, is involved in reproductive events, such as gonadal and germ cell development, as well as in sex hormone production [8]. Circulating FSH levels also undergo dramatic changes with age because of the loss of negative feedback from inhibin, as well as estrogens, in aging females [9]. Many studies have shown that activation of the renin-angiotensin system (RAS) may be involved in BP increases in postmenopausal women [10]. For example, postmenopausal women exhibit increases in plasma renin activity compared to their premenopausal counterparts [10, 11]. Interestingly, our primary study has detected FSHR in renal juxtaglomerular cells, suggesting a possible role for FSH in promoting renin secretion in postmenopausal hypertension.

The possible role of FSH and FSHR in dysfunction of the renin–angiotensin system that may be involved in BP increases in postmenopausal women has not been investigated. Considering the observed correlation between high circulating FSH levels and activation of the renin–angiotensin system in postmenopausal women, we hypothesize that FSHR might be expressed in human renal juxtaglomerular cells and that high circulating FSH levels might modulate juxtaglomerular cell functions during aging. Therefore, we performed this study to test this hypothesis.

Materials and methods

Cell culture and treatment

As4.1 cells (ATCC, Manassas, VA, USA), an immortalized renin-containing mouse renal tumor cell line, were used in this study. Cells were cultured in complete DMEM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen), 1 IU/mL penicillin (Invitrogen), and 100 µg/mL streptomycin (Invitrogen). The As4.1 cells were seeded and grown on coverslips, and then fixed with 4% paraformaldehyde (Sigma, St. Louis, MO, USA) at room temperature for 1 h. The samples were permeabilized with 0.1% Triton X-100 (Sigma) in phosphate buffered saline for 20 min. Antibody staining was performed using standard protocols as described previously [12]. Antibodies used in experiments are described in Additional file 1: Table S1. Nuclei were counterstained with DAPI for 20 min. Finally, images were analyzed under a fluorescence microscope (Olympus, Tokyo, Japan).

RT-PCR and quantitative real-time PCR analysis

Total RNA was extracted using TRIZOL Reagent (Takara, Tokyo, Japan). A 10 µg sample of total RNA was reverse transcribed into cDNA with a Prime Script™ RT reagent Kit (Takara). One microliter of cDNA was used for quantitative real-time (qRT)–PCR. PCR cycling conditions were as previously described [12] and performed in a thermal cycler (S1000™) (Bio-Rad, Foster, CA, USA). Mouse GAPDH was used as the internal control. The qRT–PCR was performed using a SYBR™ Premix ExTaq™ reagent Kit (Takara) and carried out in an Applied Biosystems 7500 Fast PCR system (ABI, Carlsbad, CA, USA). Primer sequences are listed in Additional file 1: Table S2. Data were analyzed using the comparative threshold cycle (CT) method [13].

Western blotting analysis

Samples were lysed with radioimmunoprecipitation buffer. Whole cell lysates were obtained by centrifugation at 15,000 × g for 30 min at 4 °C. After the protein concentration was determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA), whole cell lysates containing equal amounts of protein (50 µg/lane) were separated on a 10% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. Immunoblots were performed following standard procedures as described previously [12]. The antibodies used were listed in Additional file 1: Table S1. The signals were detected with enhanced chemiluminescence detection reagent (Amer sham, Piscataway, NJ, USA).

Cell transfection

Small interfering (si) RNA transfection was performed according to the manufacturer’s protocol. Briefly, 5 µL of Lipofectamine 2000 (Thermo Fisher Scientific, Shanghai, China), 20 µM of scrambled RNA (sc-44230; Santa Cruz Biotechnology, Santa Cruz, CA, USA), FSHR siRNA (sc-35415, Santa Cruz Biotechnology), and thyroid-stimulating hormone receptor (TSHR) siRNA (sc-36754, Santa Cruz Biotechnology) were diluted separately in 250 µL of serum-free Opti-MEM (Thermo Fisher Scientific) and incubated at room temperature for 5 min. The
diluted scrambled RNA/siRNA pools were then mixed with diluted Lipofectamine 2000, and incubated at room temperature for 20 min. Such scrambled RNA/siRNA-Lipofectamine 2000 complexes were added to the cell cultures. Cells were incubated at 37 °C for 6 h to recover. The cDNA of mouse FSHR was cloned into pcDNA3.1 (Thermo Fisher Scientific) at the EcoRI site. Two micrograms of pcDNAhFSHR were transfected into As4.1 cells by Lipofectamine 2000. Cells stably transfected with pcDNAhFSHR were selected by selective medium that included G418 (Thermo Fisher Scientific). Individual colonies resistant to G418 and overexpressing FSHR were obtained 20 days later.

**MTT assay**

To estimate the effect of FSH on the proliferation of As4.1 cells, 4 × 10^3 cells were treated with different concentrations of FSH (Gonal-F; Serono, Geneva, Switzerland; 0, 3, 10, 30, 100, and 300 ng/mL) following the manufacturer’s protocol in a 96-well plate. A 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazoliumbromide (MTT) assay was performed 24 h, 48 h, 72 h, and 94 h post-treatment. The absorbances of samples were measured with a spectrophotometer reader at 490 nm. Each assay was performed in triplicate and repeated three times independently.

**Intracellular cAMP assay**

As4.1 cells were treated with different concentrations of FSH (0, 3, 10, 30, 100, 300 ng/mL) for 15 min. Cyclic AMP degradation was inhibited by the addition of 100 µM isobutylmethylxanthine. After treatment, cells were lysed with 0.1 M HCl and centrifuged at 1000×g for 10 min to remove cell debris. A cAMP assay was performed by enzyme immunoassay (EIA) following the instructions of the EIA kit (901–066; Assay Designs, Ann Arbor, MI, USA).

**Radioimmunoassay**

Medium supernatants and blood samples were collected to estimate FSH, LH, estradiol, renin, and angiotensin II in mouse serum by radioimmunoassay. Serum samples were measured by standard procedures and stored at −20 °C for subsequent analysis. FSH, LH, estradiol, renin, and angiotensin II were subjected to radioimmunoassay by double-antibody precipitation methods [14]. Measurements were carried out in duplicate. Samples and standards (100 µL) were preincubated overnight at 4 °C with primary antibody (100 µL). Tracer (100 µL; iodinated FSH, LH, estradiol, renin, and angiotensin II; 12,000–15,000 cpm) was added to each tube, and the tubes were incubated for another 24 h at 4 °C. Secondary antibody (500 µL) was added and incubated for 0.5 h; water (500 µL) was then added. Bound and free tracers were separated by centrifugation (1600g) for 5 min. The supernatant containing unbound tracer was aspirated using a vacuum pump; the bound tracer in the precipitate was counted using a gamma counter.

**Animals**

Mice were obtained from the laboratory animal service center of Zhejiang University. The care and use procedures for mice were in accordance with the Institutional Guide for Laboratory Animals established by the Animal Care and Use Committee (ACUC) and were approved by the ACUC of Zhejiang University School of Medicine (Ethical Approval Number: 12,320). C57BL/6 mice (8 weeks old with body weights of 18–20 g) were housed under a 12/12-h light/dark cycle at 25±0.5 °C and 50–60% humidity and were fed ad libitum with a standard diet and water. All mice were divided into four groups (n=10 per group): (i) sham operated, (ii) OVX, (iii) OVX+GnRHa, and (iii) OVX+estrogen+FSH. In the OVX group, the mice were gonadectomized to mimic high serum FSH levels in aging populations. In the OVX+GnRHa group, gonadectomized mice were treated with GnRHa (0.5 µg/day; triptorelin acetate; Beaufour-Ipsen, Tianjin, China) by intraperitoneal injection for 8 weeks to inhibit pituitary gonadotropin secretion. In the OVX+estrogen+FSH group, castrated mice received physiological doses of estrogen in the form of daily subcutaneous injections of 0.72 mg 17β-estradiol/kg [15] (Sigma) and simultaneously were injected with recombinant FSH (0.15 IU/day; Gonal-F; Serono) by intraperitoneal injection for 8 weeks. The sham for each group received the same volume saline injection as control. All mice were maintained for 14 days before BP, endocrine levels, and renin concentrations were measured.

**SBP and DBP measurements**

SBP and DBP were non-invasively measured three times a day for three days in mice of the sham and operation groups 28 days after surgery using a computerized tail-cuff method (Softron BP98A; Softron Co., Ltd., Tokyo, Japan) as described previously [16]. The data were derived from an average of 10–20 measurements per mouse at each time point.

**Statistical analysis**

Data were presented as the mean ± standard error (SEM). A two-tailed unpaired Student’s t-test was used for comparisons between two groups. A statistical analysis was done using One-way analysis of variance (ANOVA) and Tukey HSD test for multi-comparison. The SPSS 22.0 version for Windows (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. A probability of $P < 0.05$ was considered statistically significant.

**Results**

**Expression of FSHR in juxtaglomerular cells of kidney**

The expression of FSHR (red) and renin (green) in the mouse kidney was detected by confocal double immunofluorescence. FSHR was mainly localized in the membrane of juxtaglomerular cells of the mouse kidney (Fig. 1A) and the membrane of As4.1 cells (Fig. 1B). RT-PCR and western blotting analyses confirmed the expression of FSHR mRNA and protein in mouse kidney and As4.1 cells (Fig. 1C and D).

FSH promotes renin expression and production

As4.1 cells were stimulated in a concentration-dependent manner with significant effects on renin expression at 30 and 100 ng/mL FSH ($P < 0.05$) (Fig. 2A). 30 and 100 ng/mL FSH similarly stimulated the production of renin as shown by the supernatant renin concentration in As4.1 cells cultures ($P < 0.05$) (Fig. 2B). LH (100 ng/mL) did not affect renin expression in As4.1 cell cultures ($P > 0.05$) (Fig. 2A and B). Overall, the *in vitro* results are in keeping with the expression of FSHR in juxtaglomerular cells. We attempted to distinguish the effects of FSH on proliferation versus renin synthesis in As4.1 cells. We found that FSH did not affect As4.1 cell proliferation ($P > 0.05$) (Fig. 2C) but stimulated the expression of renin at the concentration of 30 and 100 ng/ml ($P < 0.05$) (Fig. 2D). We next sought to eliminate any interaction between FSH and TSHR. FSH stimulated renin expression in TSHR knockdown but not FSHR knockdown cultures (Fig. 2E), ruling out a role for TSHR. As a further control, we overexpressed FSHR in As4.1 cells and found evidence of augmented supernatant renin concentration and renin mRNA expression compared with vector-only controls (Fig. 2Fa and b). Together, these data indicate that the FSH effects are mediated solely through the FSHR in As4.1 cells.

**High levels of FSH affect renin elevation and BP increase in mice**

In the three animal models (ovariectomy (OVX), OVX+GnRHa injection, OVX+ Estradiol (E)+ follicle stimulating hormone (FSH) injection) used in this study, we found increased serum FSH and luteinizing hormone (LH), and reduced estradiol levels in OVX animals ($P < 0.05$) (Fig. 3A, B and C), with increases in renin, angiotensin II, the heart rate (HR), SBP, DBP, and mean arterial blood pressure (MAP) ($P < 0.05$) (Fig. 3D, E, F, G, H and I). Interestingly, the increases in serum renin, angiotensin II, SBP, DBP, MAP, and HR, were obtained by additional gonadotropin-releasing hormone agonist (GnRHa) injection (Fig. 3D, E, F, G, H and I). In addition, we found that in the OVX mouse, combined with an E injection treatment with an additional FSH injection showed significant increases in renin, angiotensin II, SBP, DBP, MAP and HR when serum FSH increased ($P < 0.05$) (Fig. 3D, E, F, G, H and I). Together, these data indicate that an increased high level of serum renin, angiotensin, as well as increased BP are related to a high level of FSH in serum.
FSH activates MEK/Erk and Akt signaling pathways via Gsα to promote renin production

FSHR in renin synthesis couples with the stimulatory G protein (Gsα). The mouse As4.1 cells expressed Gsα (Fig. 4 A). Consistent with the activation of Gsα, FSH triggered a concentration-dependent increase in cyclic adenosine monophosphate (cAMP) levels, with the highest level after treatment with forskolin, an agonist of Gsα (Fig. 4B). We then examined whether FSH stimulated CREB, MAP kinase (MEK/Erk, JNK, and p38), and AKT pathways. FSH stimulated CREB, Erk1/2, AKT, and JNK phosphorylation within 10 min but did not phosphorylate p38 in As4.1 cells (Fig. 4C and D). In addition, FSH rapidly enhanced the phosphorylation of Erk1/2 and Akt as well as the expression of c-Fos in As4.1 cells (Fig. 4D–F). This suggests that Erk1/2 and c-Fos are downstream of Gsα. Consistent with this, FSH-induced increases in renin production were abrogated by NF449, a special inhibitor of Gsα in As4.1 cells (Fig. 4G). We next examined the effects of each downstream signaling pathway in mediating the functions of FSH. The MEK1/2 inhibitor, U0126, and the PKA inhibitor, H89, abrogated the FSH-induced increase in supernatant renin concentration (Fig. 4H). In the presence of the JNK inhibitor, SB600125, FSH still significantly increased renin expression (P < 0.05), although the effect was attenuated (Fig. 4I). This attenuation was in concordance with the minimal induction of JNK phosphorylation by FSH (Fig. 4C). Together, the results established that CREB, MEK/Erk, AKT, and JNK pathways contributed to the effects of FSH on renin synthesis.

Discussion

This study determined whether FSH directly affects the secretion of renin. We showed that FSH stimulated FSHR localized in juxtaglomerular cells to produce renin in vitro and in vivo. These actions are exerted via a Gsα-coupled FSHR that triggers MEK/Erk and Akt signaling pathways. The increased high level of serum renin and
angiotensin as well as increased BP are related to the high level of FSH in serum of animal models, even in the presence of normal estrogen levels. This indicates an estrogen-independent action of FSH on BP regulation.

FSH levels are drastically increased during aging [9], especially in postmenopausal females, but the contributions of FSH to aging processes are remain unclear. Several physiological systems have been implicated in clinical studies. For example, postmenopausal women exhibit increases in plasma renin activity compared to their premenopausal counterparts [10, 17]. This suggests that increased FSH levels are correlated with known cardiovascular disease (CVD) risk factors and reveals the critical roles of FSH in renin activity. Our present study demonstrates that FSHRs are expressed in the juxtaglomerular cells of the mouse kidney, and a mouse juxtaglomerular cell line. This suggests a possible role for high FSH levels in the serum renin increase observed in aging subjects.

Fig. 3  High level FSH, not low estrogen, increased the mouse serum rennin levels and BP. The serum FSH (A), LH (B), E2 (C), rennin (D) and angiotensin (E) in different treatment groups. The SBP (F), DBP (G), MAP (H) and HR (I) in different treatment groups. Data are presented as mean ± SEM. 10 mice/group, *P<0.05, **P<0.01, ***P<0.001, compared with the corresponding controls. ns, not significant. S, sham group, O, O VX (ovariectomized mice); O + G (ovariectomized mice injected with GnRHa); O + E + F (ovariectomized mice injected with estrogen and FSH). 

P-values for panel A were 0.00026, 0.00018, respectively. P-value for panel B was 0.0318. P-values for panel C were 0.00054, 0.00032, respectively. P-values for panel D were 0.0065, 0.0047, respectively. P-values for panel E were 0.0266, 0.0187, respectively. P-values for panel F were 0.0412, 0.0375, respectively. P-values for panel G were 0.0306, 0.0285, respectively. P-values for panel H were 0.0446, 0.0349, respectively. P-values for panel I were 0.0415, 0.0307, respectively.
Fig. 4  FSH activates Erk, Akt, and CREB via Gsα to produce rennin in As4.1 cells. A Western blotting results shows Gsα isoforms is expressed in As4.1 cells. B Effect of FSH and forskolin (Forskol, 10 mM) on cAMP levels in As4.1 cells cultures. Data are presented as mean ± SEM; n = 5; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the 0ng/ml FSH treatment. P-values were 0.03228, 0.00574, 0.00072 respectively. C–F Western blots of phosphorylated (p-) Erk1/2, Akt, CREB, JNK, or p38 levels or nuclear c-Fos levels in As4.1 cells in response to FSH. Data are presented as mean ± SEM; n = 5; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the 0ng/ml FSH treatment. P-values for panel C were 0.0069, 0.0297, respectively. P-values for panel D were 0.00533, 0.00229, 0.00076, respectively. P-values for panel E were 0.00178, 0.00043, respectively. P-values for panel F were 0.03985, 0.00085, respectively. G Effect of FSH on rennin concentration in the supernatant of As4.1 cells cultures after Gsα was inhibited by NF449 (100ng/mL). Data are presented as mean ± SEM; n = 5; *P < 0.05, **P < 0.01, compared with the 0ng/ml FSH treatment. P-values were 0.0414, 0.0075, respectively. H Effect of PKA inhibitors H89 (30 µM) and MEK1/2 inhibitors U0126 (0.5 mM) on rennin concentration in the supernatant of As4.1 cells cultures in response to 30 ng/ml FSH treatment. Data are presented as mean ± SEM; n = 5; **P < 0.01, compared with the corresponding controls. P-values were 0.0082, 0.0061, 0.0047, respectively. I Quantitative real-time PCR showing the effect of the MEK1/2 inhibitors U0126 (0.5 mM) or JNK inhibitors SB600125 (0.5 mM) on rennin mRNA expression in 48-hour cultures. Data are presented as mean ± SEM; n = 5; *P < 0.05, **P < 0.01, ***P < 0.001, compared with the corresponding controls. P-values were 0.0056, 0.0309, respectively.
In the adult kidney, renin is synthesized by myofibroblast-like cells that are located at the medial layer of renal afferent arterioles at the entrance to the glomerular capillary network [18]. Only juxtaglomerular cells in the kidney are capable of generating active renin from prorenin, which is stored in prominent vesicles and released into the circulation upon demand [18]. Using mouse juxtaglomerular cell lines in vitro, we demonstrated that FSH directly stimulated juxtaglomerular cells to produce renin. In addition, FSH did not affect cell proliferation but stimulated the expression of renin. Considering the increase of supernatant renin concentration, FSH stimulated juxtaglomerular cells to release renin from the cytoplasm. FSHRs are members of the TSHR/LHR/FSHR superfamily [19]. We therefore sought to examine whether FSH displayed an agonistic action toward the TSHR. We found that FSH elicited a full renin expression response in TSHR knockdown cultures, ruling out a role for TSHRs. We further established specificity by showing enhanced renin expression in FSHR-overexpressing cultures.

We found that the FSHRs localized in juxtaglomerular cells were coupled to Gsa, the major Gs isoform to form complete G protein coupled receptor (GPCRs). FSH-induced increases in cAMP levels attest to this coupling. Whereas a similar coupling of the FSHR to Gsa has been noted in granulosa cells in the ovarian follicle [20], FSH actions in juxtaglomerular and Sertoli cells are mediated via Gia [21, 22]. It has previously been reported that binding of FSH to its receptor results in adenylyl cyclase activation leading to cAMP synthesis, which is associated with the activation of phosphorylated CREB [23, 24], protein kinase A, and MAP kinase pathways [21, 25]. The effects of FSH on Erk1/2, Akt, CREB activation, and c-Fos expression were all investigated in juxtaglomerular cells. Consistent with this, FSH-induced increases in renin concentration in the culture medium were abrogated by NF449, a Gsa inhibitor. This suggests that Erk1/2, CREB, Akt, and c-Fos are downstream of FSHR for the synthesis of renin in juxtaglomerular cells. We also find that FSH-induced renin synthesis is attenuated by MEK inhibitors but not by a JNK inhibitor, indicating that the MEK/Erk pathway is essential. The synthesis of renin that was increased by FSH was also abrogated by NF449, a Gsa inhibitor. Overall, FSH activates Erk1/2, Akt, and CREB, but not p38 and JNK, to stimulate renin synthesis in juxtaglomerular cells.

Because the primary mechanisms underlying a cardiovascular protective effect have been attributed solely to estrogen in the past [26], the direct action of FSH on renin synthesis has never been explored. Increased FSH levels in post-menopausal women likely cause age-related cardiovascular disorders. This notion is supported by the results obtained from OVX mice, which provide an experimental model of the high FSH levels observed in aging women [27]. We thus examined the in vivo effects of OVX, or ectogenic estrogen and FSH after OVX, on renin synthesis. Despite persistent low estradiol levels, GnRHa reversed OVX-induced changes in BP and HR in mice. Hence, high FSH and/or LH levels are possibly responsible for cardiovascular disorders in aging women [28, 29]. However, the replenishment of recombinant FSH in OVX mice that received ectogenic physiological doses of estrogen resulted in a significant increase in BP and HR, which excludes the possible effect of LH and low estrogen; this result affirmed that FSH is responsible for cardiovascular disorders. Similar with the results obtained in vitro, studies with OVX mice also showed that FSH was responsible for the increased serum levels of renin and angiotensin II. Moreover, FSH was implicated in increased renin synthesis in vivo. These results indicated the contribution of FSH to renin-related cardiovascular disorders in mice. Nevertheless, further studies should be conducted to confirm this possibility.

There were still some limitations in this study. The interaction between FSHR and Gsa has not been evaluated. Histology analysis and serum biomarkers such as urine, creatinine for kidney function have not been performed in this study. The related pathways of the involvement of FSH in a renin synthesis disorder have not been evaluated. The renin concentration of FSHRs in TSHR knockdown conditions was not investigated and whether FSH displayed an agonistic action toward the LHR has also not been evaluated.

**Conclusions**

In conclusion, our findings revealed a potential role for FSH in promoting renin synthesis in humans. Our results also outlined a new molecular mechanism for age-related cardiovascular disorders in women. High levels of FSH, rather than decreased levels of sex hormones, are possibly responsible for an increase of renin in serum in aging populations of females. This study demonstrated that FSH was involved in a renin synthesis disorder. Along with high FSH levels commonly observed in aging women, FSHR might be considered a potential therapeutic target to reduce the risk of age-related cardiovascular disorder and diseases.

**Abbreviations**

FSH: Follicle stimulating hormone; FSHRs: Follicle stimulating hormone receptors; OVX: Ovariectomy; HR: Heart rate; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial blood pressure; BP: Blood pressure; RAS: Renin-angiotensin system; ACUC: Animal Care and Use Committee;
Acknowledgements

We thank Dr. S. Yu (Medical School, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China) for providing the vector expressing mouse FSHR (pcDNAhFSHR).

Authors’ contributions

ZY is responsible for study design, literature research, experimental studies, data analysis, manuscript preparation; WJH is responsible for the data analysis; TZ is responsible for the data analysis, statistical analysis, XML and WZ are responsible for the data acquisition; YXL is responsible for the manuscript editing & review; YCL is responsible for the the guarantor of integrity of the entire study, study concepts & design, definition of intellectual content, manuscript review. All authors read and approved the final manuscript.

Funding

This work was supported by Natural Science Foundation of China (No.81671418), National Key Research and Development Program of China (2018YFC1003202) and Zhejiang Provincial Natural Science Foundation of China (LY17H040004).

Availability of data and materials

All data generated or analysed during this study are included in this. Further enquiries can be directed to the corresponding author.

Declarations

Ethics approval and consent to participate

The care and approval for procedures for mice were in accordance with the Institutional Guide for Laboratory Animals established by the Animal Care and Use Committee (ACUC), and were approved by the ACUC of Zhejiang University School of Medicine (Ethical Approval Number: 13230).

Consent for publication

Not applicable.

Competing interests

The authors have no conflict of interests to declare.

Author details
1. Department of Reproductive Endocrinology, Women’s Hospital, Zhejiang University School of Medicine, No. 1 XueShi Road, Hangzhou 310006, Zhejiang, China. 2. Department of Gynecology, Shangyu People’s Hospital of Shaoxing, Shangyu, Shaoxing 312300, Zhejiang, China. 3. Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China.

Received: 1 December 2021   Accepted: 14 March 2022
Published online: 03 May 2022

References

1. Ong KL, Tso AW, Lam KS, Cheung BM. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. 2008;51:1142–8.
2. Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291–7.
3. Wu S, Jin C, Li S, Zheng X, Zhang X, Cui L, Gao X. Aging, arterial stiffness, and blood pressure association in Chinese adults. Hypertension. 2019;73:893–9.
4. Barton M, Meyer MR. Postmenopaual hypertension: mechanisms and therapy. Hypertension. 2009;54:11–8.
5. Winberg N, Håreholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen PE, Svendsen TL, Kampmann JP, Madsen NH, Bentzon MW. 24-h ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens. 1995;8:978–86.
6. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25:305–13.
7. Kim JK, Alley D, Seeman T, Karlamarangla A, Crimmins E. Recent changes in cardiovascular risk factors among women and men. J Womens Health (Larchmt). 2006;15:734–46.
8. Simon J, Gromoll J, Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, and pathology. Endocr Rev. 1997;18:739–73.
9. Ausman RJ, Tan DA, Jasamsun L, Tian XW, Holinka CF, Estradiol. FSH and LH profiles in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study. Climacteric. 2007;10:427–37.
10. Fernández-Vega F, Abellán J, Vegoazo O, De Vinuesa SG, Rodríguez JC, Maceira B, de Castro SS, Nicolás RR, Luño J. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy. Kidney Int Suppl. 2002;62:536–41.
11. Schenkert H, Danser AH, Henze HW, Derks FH, Kürzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation. 1997;95:39–45.
12. Zhang RJ, Zou LB, Zhang D, Tan YJ, Wang TT, Lü AX, Qu F, Meng Y, Ding GL, Lu YC, Lv PP, Sheng JZ, Huang HF. Functional expression of large-conductance calcium-activated potassium channels in human endometrium: a novel mechanism involved in endometrial receptivity and embryo implantation. J Clin Endocrinol Metab. 2012;97:543–53.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(‑Delta Delta C(T)) Method. Methods. 2001;25:402–8.
14. Crowe MA, Padmanabhan V, Hynes N, Sunderland SJ, Enright WJ, Beitins IZ, Roche JF. Validation of a sensitive radioimmunoassay to measure serum follicle-stimulating hormone in cattle: correlation with biological activity. Anim Reprod Sci. 1997;48:123–36.
15. Tang AC, Nakazawa M, Romero RD, Rhee BC, Sisti H, McEwen BS. Effects of long-term estrogen replacement on social integration and social memory in ovariectomized C57BL/6 mice. Horm Behav. 2005;47:350–7.
16. Wang Y, Yoshikawa K, Azam MA, Takuya N, Sakurada S, Kayaba Y, Sugimoto N, Inoki I, Kimura T, Kusukata T, Takuya Y. Clas II phosphonostide 3-kine alpha isoform regulates Rho, myosin phosphatase and contraction in vascular smooth muscle. Biochem J. 2006;394:581–92.
17. Yanes LL, Romero DG, Iliescu R, Zhang H, Davis D, Rechelhoff JF. Postmenopausal hypertension: role of the Renin-Angiotensin system. Hypertension. 2010;56:359–63.
18. Kurtz A. Control of renin synthesis and secretion. Am J Hypertens. 2012;25:839–47.
19. Ulløa-Aguirre A, Uribe A, Zarinán T, Bostos-Jaimes P, Pérez-Solís MA, Dias JA. Role of the intracellular domains of the human FSH receptor in G(alphaS) protein coupling and receptor expression. Mol Cell Endocrinol. 2007;260–262:153–62.
20. Conti M. Specificity of the cyclic adenosine 3′,5′-monophosphate signal in granulosa cell function. Biol Reprod. 2002;67:1653–61.
21. Casarini L, Crépieux P. Molecular mechanisms of action of FSH. Front Endocrinol (Lausanne). 2019;10:305.
22. De Pascali F, Trifier A, Landiomef B, Bozon V, Bruneau G, Yviner R, Poupou A, Crépieux P, Reiter E. Follicle-stimulating hormone receptor: advances and remaining challenges. Int Rev Cell Mol Biol. 2018;338:1–58.
23. Rice S, Elia A, Jawad Z, Pellatt I, Mason HD. Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E1:491–500.
24. Cui H, Zhao G, Wen J, Tong W. Follicle-stimulating hormone promotes the transformation of cholesterol to estrogen in mouse adipose tissue. Biochem Biophys Res Commun. 2018;495:2331–7.
25. Ning G, Ouyang H, Wang S, Chen X, Xu B, Yang J, Zhang H, Zhang M, Xia G. 3'5'-cyclic adenosine monophosphate response element binding protein up-regulated cytochrome P450 lanosterol 14alpha-demethylase expression involved in follicle-stimulating hormone-induced mouse oocyte maturation. Mol Endocrinol. 2008;22:1682–94.
26. Murphy E, Steenbergen C. Cardioprotection in females: a role for nitric oxide and altered gene expression. Heart Fail Rev. 2007;12:293–300.
27. Hsueh AJ, Erickson GF. Extrapituitary action of gonadotropin-releasing hormone: direct inhibition ovarian steroidogenesis. Science. 1979;204:854–5.
28. Zhu D, Li X, Macrae VE, Simoncini T, Fu X. Extragonadal effects of follicle-stimulating hormone on osteoporosis and cardiovascular disease in women during menopausal transition. Trends Endocrinol Metab. 2018;29:571–80.
29. Sohrabi F, Okoreeh A, Panta A. Sex hormones and stroke: beyond estrogens. Horm Behav. 2019;111:87–95.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.